ARKRAY FACTORY USA, INC.
2 recall(s) on record — most severe on record: Class I.
Activity by year
- Recalls (2)
- Inspections (1)
Devices registered here (1)
- Multiple Use Blood Lancet For Single Patient Use OnlyProduct code QRL (opens in a new tab) · Class II · General, Plastic Surgery · 21 CFR 878.4850
Recalls & enforcement
- Class IITerminated2019-05-03This correction is being initiated due to a software issue which results in the possibility of incorrect patient information being assigned to sample results when the following rare combination of three specific events were to occur: 1) No measurement results are generated due …
- Class ITerminated2015-12-18One lot each of SPOTCHEM II Basic PANEL-1 Reagent Test Strip and SPOTCHEM II Glucose Reagent Test Strip are being recalled due to a lowered reaction rate in the reagent pad for glucose. The affected lots will display a result of approximately 300 to 400 mg/dL for any glucose val…
FDA inspections (1)
- NAI2016-08-16No Action Indicated · Compliance: Devices
Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.
Related
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)
Cite this record
RegWarden. “ARKRAY FACTORY USA, INC. (FEI 1832816) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/1832816-arkray-factory-usa-inc/
Alerts for ARKRAY FACTORY USA, INC.
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.